Jasper Therapeutics (JSPR) PT Lowered to $6 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts JSPR Hot Sheet
Price: $0.51 +6.25%
Rating Summary:
11 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
11 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Cantor Fitzgerald analyst Pete Stavropoulos lowered the price target on Jasper Therapeutics (NASDAQ: JSPR) to $6.00 (from $10.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Jasper Therapeutics enacts 1-for-30 reverse stock split
- GXO Logistics Inc. (GXO) PT Raised to $72 at TD Cowen
- Datadog (DDOG) PT Lowered to $245 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
